Proclara Biosciences Stock
Proclara is pioneering a new approach to treating neurodegenerative diseases.
Sign up today and learn more about Proclara Biosciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Proclara Biosciences Stock
NeuroPhage Pharmaceuticals, Inc. is a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. It offers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Funding History
| March 2008 | $7.0M |
|---|---|
| March 2011 | $12.4M |
| March 2012 | $9.0M |
| May 2013 | $6.4M |
| March 2014 | $17.0M |
| January 2015 | $10.0M |
| September 2016 | $47.0M |
| November 2018 | $6.9M |
Management
Member of the Board of Directors
Vicki Sato
Scientific Advisory Board
Cynthia Lemere
Co-founder and Scientific Advisor
Beka Solomon
Scientific Advisors
Paul Aisen
Scientific Advisory Board
Greg Petsko
SVP Preclinical Research and Development
Kimberley Gannon
Clinical Development Leader
Michael Grundman
Board of Directors
Paul D. Goldenheim
VP Regulatory and Compliance
Roxanne Bales
Board of Directors
Kenneth Buckfire
Scientific Advisory Board
Andres Lozano
Member of the Scientific Advisory Board
David Holtzman
Scientific Advisor
David Hafler
Board of Directors
Saira Ramasastry
Board of Directors
Nico Dosenbach
Board of Directors
John F. Dee
Board of Directors
Peter Smedvig
Press
businesswire - Mar, 29 2018
Proclara Biosciences Presents Preclinical Data Supporting the Development of GAIM-Based Therapies for Peripheral Amyloidoses at the 16th International Symposium on Amyloidosisfiercebiotech - Jan, 3 2018
Proclara nabs Merck Alzheimer’s R&D executivexconomy - Nov, 3 2016
Bio Roundup: Cancer Wishes and Shopping Lists, Allergan Pricing & Morexconomy - Nov, 2 2016
With New Name and $47M, Proclara Begins First Big Alzheimer’s Testprnewswire - May, 2 2016
Promising New Treatments For Alzheimer's Target Multiple Disease-related Proteins; May Have Benefits For Several Brain Diseasesfinsmes - Sep, 29 2015
NeuroPhage Pharmaceuticals Raises $12.4M in Series B Financingfinsmes - Sep, 29 2015
NeuroPhage Pharmaceuticals Raises $10.0M in Series D Financingfiercebiotech - Sep, 29 2015
AcelRx CEO Richard King steps downxconomy - Sep, 29 2015
Apperian, Exinda, Adelphic, & More Boston-Area Dealmakersxconomy - Sep, 29 2015
SavingStar, Exinda, & NeuroPhage: A Trio of Boston Startup Dealsxconomy - May, 21 2015
RXi Sells Stock and Warrants, Cardiorobotics Raises $6.6M, ImmunoGen Dishes On New Drugs, & More Boston-Area Life Sciences News | Xconomyfinsmes - Mar, 26 2014
FinSMEs | NeuroPhage Pharmaceuticals Completes $17M Series D FinancingEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
